Not very practical where it counts

By Steve Usdin

Contributing Editor WASHINGTON - The Medicare prescription drug benefit proposal released by President Clinton last week is unlikely to be of much benefit either to biotech companies or very sick patients, and it has features that could limit access to innovative treatments, according to industry analysts here. ...